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S U M M A R Y
Background: The level of rubella susceptibility among women of reproductive age in Namibia is
unknown. Documenting the risk of rubella will help estimate the potential burden of disease in
Namibian women and the risk of congenital rubella syndrome (CRS) in infants, and will guide strategies
for the introduction of rubella vaccine.
Methods: A total of 2044 serum samples from pregnant Namibian women aged 15–44 years were tested
for rubella immunoglobulin G antibody; the samples were obtained during the 2010 National HIV
Sentinel Survey. The proportion of women seropositive for rubella was determined by 5-year age strata,
and factors associated with seropositivity were analyzed by logistic regression, including age, gravidity,
HIV status, facility type, and urban/rural status.
Results: Overall rubella seroprevalence was 85% (95% conﬁdence interval (CI) 83–86%). Seroprevalence
varied by age group (83–90%) and health district (71–100%). In the multivariable model, women from
urban residences had higher odds of seropositivity as compared to women from rural residences (odds
ratio 1.40, 95% CI 1.09–1.81).
Conclusions: In the absence of a routine rubella immunization program, the high level of rubella
seropositivity suggests rubella virus transmission in Namibia, yet 15% of pregnant Namibian women
remain susceptible to rubella. The introduction of rubella vaccine will help reduce the risk of rubella in
pregnant women and CRS in infants.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Rubella is a vaccine-preventable viral disease that is character-
ized by a febrile illness and rash.1 Rubella infection in pregnant
women can lead to congenital rubella syndrome (CRS), which can
result in severe illness, disability, and death in the fetus.2DOI of original article: http://dx.doi.org/10.1016/j.ijid.2016.05.020
§ The ﬁndings and conclusions in this report are those of the authors and do not
necessarily represent the ofﬁcial position of the Centers for Disease Control and
Prevention.
* Corresponding author. Tel.: +1 404 639-8241; fax: +1 404 417-0962.
E-mail address: iyk8@cdc.gov (C.V. Cardemil).
http://dx.doi.org/10.1016/j.ijid.2016.05.009
1201-9712/Published by Elsevier Ltd on behalf of International Society for Infectious
creativecommons.org/licenses/by-nc-nd/4.0/).Worldwide, more than 100 000 children are born each year with
CRS.3,4
From 2000 to 2009, reported rubella cases increased 20-fold in
the World Health Organization (WHO) African Region.5 Despite
this increase in reported number of cases, as of 2015, there is no
rubella elimination, control, or prevention goal in the African
Region.4 Thus far, a small number of Sub-Saharan African countries
have introduced rubella-containing vaccine in their Expanded
Programme on Immunization (EPI) childhood immunization
schedule (Burkina Faso, Ghana, Rwanda, Senegal, and Tanzania),
and others are planning to do so in the next few years.1
The WHO recommends that countries without rubella vaccine
assess the burden of rubella and CRS.6 Serosurveys have suggested Diseases. This is an open access article under the CC BY-NC-ND license (http://
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published studies have investigated seroprevalence in Namibia.
Currently, rubella-containing vaccine (RCV) is not available
publicly in Namibia. Understanding the level of rubella suscepti-
bility in pregnant women in Namibia will provide important
information to help determine the burden of disease and the need
for the introduction of rubella vaccine.8
Namibia is a country in southwestern Africa that gained
independence from South Africa in 1990. It has an estimated
population of 2.1 million.9 The capital city is Windhoek, and the
country is administratively organized into 34 health districts in
14 regions, including those with the highest populations in the
northern part of the country along the border with Angola, and in
the central and the southern parts of the country.10 The majority
(57%) of Namibian residents are rural dwellers.9 In 2014, Namibia
had one of the highest HIV prevalence rates for adults aged 15–49
years in the world at 16.0%;11 overall prevalence was high
compared with other countries in the Sub-Saharan Africa region.12
The total fertility rate has been estimated at 3.1 per woman and the
crude birth rate at 26 per 1000 population.13
To evaluate rubella immunity in pregnant women 15–44 years
of age and examine factors associated with seropositivity, stored
serum samples from the 2010 Namibia National HIV Sentinel
Survey were tested. Rubella immunoglobulin G (IgG) antibody
seroprevalence estimates will provide evidence to support the
decision to introduce rubella vaccine as part of the Namibia
national EPI and to guide efforts to prevent rubella and CRS.
2. Methods
In 2010, the Namibia Ministry of Health and Social Services
(MoHSS) conducted a nationwide sentinel survey to estimate HIV
prevalence in pregnant women aged 15–49 years. The survey was
designed using the standardized WHO methodology for HIV
prevalence surveys, using convenient consecutive sampling of
women attending antenatal clinics (ANC) selected based on
geographic representation from all regions and health districts,
urban and rural clinics, areas with different population densities
and sizes, and women of different socioeconomic status.14,15 All
pregnant women aged 15–49 years were included in the survey if
they attended an ANC for the ﬁrst time during their current
pregnancy, were not referred from another health facility, and
agreed to a routine blood draw.
The 2010 survey enrolled 7983 pregnant women from all
34 health districts, 35 main hospitals, and 93 satellite health centers
and clinics; 7888 (98.8%) of the enrollees had specimens collected
during March 22 to September 6, 2010.15 Unlinked, de-identiﬁed
specimens were tested for HIV antibodies. All de-identiﬁed dataTable 1
Target and observed sample sizes among pregnant women aged 15–44 years by age g
Age group, years HIV status Total specimens Target sample size 
15–19 Positive 86 32 
Negative 1264 450 
20–24 Positive 282 60 
Negative 1994 422 
25–29 Positive 410 110 
Negative 1398 372 
30–34 Positive 373 145 
Negative 871 337 
35–39 Positive 222 144 
Negative 523 338 
40–44 Positive 71 71 
Negative 211 211 
All ages Both 7705 2692 ﬁelds (unique identiﬁcation, district abbreviation and site number,
facility type, date of ANC visit, woman’s age, gravidity, place of
residence, antiretroviral therapy participation, and counseling for
prevention of maternal-to-child transmission) were retained
electronically. Specimens were stored at 4–8 8C at the Namibia
Institute of Pathology in Windhoek.
To estimate the prevalence of rubella IgG antibody within each
5-year age group, it was determined that 428 specimens in each
age group would be necessary, assuming seroprevalence of 50%,
desired precision of 5%, probability of achieving the desired
precision of 0.95, and 10% loss due to specimens not found or
inadequate. There were too few specimens in the 45–49 years age
stratum for meaningful estimates, so these samples were excluded.
The number of specimens in the 40–44 years age stratum was less
than the targeted number, so all specimens were sampled. To control
for the distribution of HIV-infected women within each age group, the
target sample size was allocated to the HIV-positive and HIV-negative
groups based on their observed distributions in the sentinel survey.15
Testing for rubella IgG antibody was performed by the Namibia
Institute of Pathology in 2012, using an enzyme immunoassay (EIA)
to detect rubella-speciﬁc IgG (Enzygnost; Siemens, Germany); tests
were performed in accordance with the manufacturer’s recom-
mendations. Samples with corrected optical density (OD) values
>0.2 were considered positive, samples with values <0.1
were considered negative, and samples with values of 0.1–0.2
were considered equivocal. Specimens that tested equivocal were
retested as per the manufacturer’s instructions, and if the result was
conﬁrmed, samples were classiﬁed as equivocal, otherwise as
positive or negative. To monitor the performance of the EIA, an in-
house positive control for rubella IgG antibody was included on
every EIA plate in addition to the controls supplied by the
manufacturer. A 5% random sample of specimens were tested at
the US Centers for Disease Control and Prevention (CDC, Atlanta, GA,
USA) for quality assurance; high concordance was found with the
testing at the Namibia Institute of Pathology (results not shown).
Seroprevalence estimates and 95% conﬁdence intervals (CI) were
calculated using the Wilson-score method for each 5-year age group
and for the following sub-groups: gravidity, HIV status, urban/rural
residence, facility type (hospital, health center, or clinic), and health
district. The odds of seropositivity were calculated by multiple
logistic regression while controlling for age group, gravidity, HIV
status, urban/rural residence, and facility type. All analyses included
sampling weights, which were calculated based on the probability of
selection within each of the 12 age–HIV strata and adjusted for non-
response (i.e., specimens not available or inadequate for testing) in
each of the strata by the propensity cell adjustment method. These
weights were then scaled to the total sample size: (weight/sum of
weights)  total sample. A large percentage of specimens were notroup and HIV status, from the 2010 Namibia National HIV Sentinel Survey
% of total specimens
sampled
Observed sample size % Not tested
(target-observed/
target)
37 24 25
36 335 26
21 46 23
21 321 24
27 81 26
27 283 24
39 110 24
39 259 23
65 115 20
65 252 25
100 53 25
100 161 24
35 2040 24
Table 3
Logistic regression calculating the odds of rubella seropositivity among pregnant
women aged 15–44 years, from the 2010 Namibia National HIV Sentinel Survey
OR 95% CI p-Value
Age group, years 0.318
15–19 Ref.
20–24 1.16 0.78–1.70 0.467
25–29 0.85 0.54–1.33 0.478
30–34 1.18 0.70–2.36 0.534
35–39 1.27 0.68–2.36 0.453
40–44 1.57 0.64–3.84 0.323
Facility 0.065
Hospital Ref.
Health center 0.77 0.49–1.21 0.248
Clinic 1.12 0.77–1.65 0.552
HIV status 0.661
Positive Ref.
Negative 0.93 0.67–1.29 0.661
Gravidity 0.446
1 Ref.
2 1.23 0.85–1.76 0.273
3 0.95 0.62–1.44 0.809
4+ 1.20 0.76–1.90 0.433
Setting 0.007
Rural Ref.
Urban 1.41 1.10–1.82 0.007
OR, odds ratio; CI, conﬁdence interval.
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was available for all women sampled, so multiple imputation using
chained equations was conducted to impute seropositivity, and the
imputed results were compared with estimates based on the subset
of non-missing data. As the imputed estimates were not substan-
tially different from the estimates based on the complete non-
missing data, only the laboratory results from complete specimens
tested are reported. The multiple imputations were done using the
mice package in R statistical software version 3.1.2. Other data were
analyzed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Comparisons of seroprevalence among groups were done using the
Chi-square test on the weighted data. This study received ethical
approval from the CDC and the Namibia MoHSS.
3. Results
Based on the sample size calculation, 2692 specimens were
selected for inclusion in the study (Table 1); of these, 389 (14%)
were not available, 230 (8%) had insufﬁcient volume, 29 (1%) were
hemolyzed and therefore could not be used for laboratory testing,
and four (0.1%) had a missing test result, resulting in 2040 speci-
mens that were tested and had a laboratory result.
Overall rubella seroprevalence was 85% (95% CI 83–86%)
(Table 2). While the 15–19 years age group had the lowest
observed seroprevalence (83%) and the 40–44 year old age group
had the highest (90%), no statistically signiﬁcant difference among
age groups was seen (p = 0.208). Seroprevalence was found to
differ by type of facility (p = 0.033). Women from urban residences
had higher seroprevalence (87%) compared with women from rural
residences (83%) (p < 0.001).
The multivariable model calculated the odds of rubella
seropositivity while adjusting for age group, gravidity, HIV
status, urban/rural residence, and facility type (Table 3). Women
from urban residences had higher odds of seropositivity as
compared with women from rural residences (odds ratio 1.41,
95% CI 1.10–1.82).
Rubella seroprevalence varied by health district and urban/
rural residence, from 71% to 100% (Table 4). An analysis comparingTable 2
Rubella seroprevalence among pregnant women aged 15–44 years, overall and by age gr
HIV Sentinel Survey
Unweighted
total, N
Weighted
percent
positive
95% CIa p
Overall 2040 85 83–86 
Age group, years 
15–19 359 83 79–87 
20–24 367 86 83–88 
25–29 364 82 78–85 
30–34 369 86 82–90 
35–39 367 88 82–91 
40–44 214 90 81–95 
Facility 
Hospital 232 84 79–88 
Health center 301 80 75–84 
Clinic 1507 86 84–88 
HIV status 
Positive 429 86 82–89 
Negative 1611 85 83–86 
Gravidity 
1 566 84 81–86 
2 396 86 83–89 
3 349 83 79–87 
4+ 729 87 84–89 
Setting <
Rural 1129 83 81–85 
Urban 911 87 85–89 
CI, conﬁdence interval.
a Wilson score.demographics of the women whose specimens were not available,
of insufﬁcient volume, or hemolyzed, with the characteristics of
women whose specimens were tested and included in the analysis,
found no substantial differences by age group, gravidity, HIV
status, or urban/rural residence (data not shown).
4. Discussion
In 2010, rubella IgG antibody seroprevalence among pregnant
women sampled by the National HIV Sentinel Survey in Namibia
was 85%. Women residing in urban settings had higher rubella
seroprevalence than those in rural settings. Variation was observed
in rubella seroprevalence by health district; the lowest pointoup, facility type, HIV status, gravidity, and setting, from the 2010 Namibia National
-Value Weighted
percent
negative
95% CIa Weighted
percent
equivocal
95% CIa
- 12 10–14 3 2–4
0.208
14 10–18 3 2–6
11 9–14 3 2–5
14 11–18 4 2–6
12 9–16 2 0.7–4
8 5–13 4 2–8
7 3–15 4 1–11
0.033
16 12–21 0.4 0.1–2
17 13–21 3 2–6
11 9–12 4 3–5
0.594
12 9–16 2 1–4
12 11–14 3 3–4
0.294
13 11–16 4 2–5
11 9–14 3 2–5
13 10–17 4 2–6
11 8–14 3 2–5
0.001
14 12–16 4 3–5
10 8–12 3 2–4
Table 4
Rubella seroprevalence among pregnant women aged 15–44 years, by health district and urban/rural status, from the 2010 Namibia National HIV Sentinel Survey
District Setting Unweighted, n Weighted
% positive
95% CI Weighted
% negative
95% CI Weighted
% equivocal
95% CI
Andara Rural 53 89 78–95 11 5–23 0 0–7
Urbana 0
Aranos Rural 14 100 83–100 0 0–17 0 0–17
Urban 2 100 36–100 0 0–64 0 0–64
Eenhana Rural 67 86 76–92 9 4–18 5 2–14
Urbana 0
Engela Rural 71 71 60–81 17 10–28 11 6–21
Urban 1 100 30–100 0 0–70 0 0–70
Gobabis Rural 11 100 73–100 0 0–27 0 0–27
Urban 55 93 84–97 7 3–16 0 0–6
Grootfontein Rural 10 76 47–92 24 8–53 0 0–26
Urban 40 88 76–95 12 5–25 0 0–8
Oshakati Rural 41 88 74–95 7 2–19 5 2–17
Urban 38 72 57–84 20 11–35 8 3–20
Karasburg Rural 11 77 47–93 10 2–40 12 3–42
Urban 26 100 87–100 0 0–13 0 0–13
Katutura Rurala 0
Urban 76 94 87–98 5 2–13 0.4 0–6
Keetmanshoop Rural 17 89 65–97 3 0.4–24 8 2–31
Urban 29 91 75–97 9 3–25 0 0–12
Khorixas Rural 20 100 83–100 0 0–17 0 0–17
Urban 21 88 64–97 6 1–29 6 1–29
Katima Mulilo Rural 26 89 72–96 11 4–28 0 0–13
Urban 65 89 80–95 10 5–20 0.5 0–6
Lu¨deritz Rural 20 84 63–94 8 2–26 9 2–28
Urban 54 96 87–99 4 1–13 0 0–7
Mariental Rural 23 87 68–96 13 4–32 0 0–14
Urban 18 91 71–98 7 1–26 3 0.3–21
Nankudu Rural 36 76 61–87 24 13–40 0 0–9
Urbana 0
Nyangana Rural 66 86 76–92 14 8–25 0 0–5
Urban 9 81 50–95 10 2–40 10 2–40
Okahao Rural 102 79 69–86 19 12–28 3 0.8–8
Urbana 0
Okahandja Rurala 1
Urban 53 85 73–92 10 5–22 5 1–14
Okakarara Rural 35 81 65–91 19 9–35 0 0–10
Urban 13 76 49–91 24 9–51 0 0–22
Okongo Rural 88 86 76–92 7 3–16 7 3–15
Urbana 0
Omaruru Rural 29 90 71–97 5 0.8–23 5 0.8–23
Urban 23 87 69–96 6 1–22 7 2–24
Onandjokwe Rural 85 79 68–86 21 13–31 0.7 0–6
Urbana 0
Opuwo Rural 17 75 49–91 15 4–41 10 2–35
Urbana 0
Oshikuku Rural 70 82 71–89 17 10–28 1 0.2–7
Urbana 0
Otjiwarongo Rurala 0
Urban 62 86 75–92 11 5–21 4 1–12
Outjo Rural 39 77 62–88 21 11–37 1 0.2–11
Urban 21 73 53–87 3 0.3–19 24 11–45
Outapi Rural 49 79 66–88 11 5–22 10 5–22
Urbana 1
Rehoboth Rural 4 100 52–100 0 0–48 0 0–48
Urban 22 84 64–94 12 4–31 4 0.7–21
Rundu Rural 12 87 57–97 5 0.6–33 9 2–37
Urban 55 92 82–96 6 2–15 3 0.7–11
Swakopmund Rurala 0
Urban 56 88 77–94 10 5–20 2 0.4–9
Tsandi Rural 87 82 72–89 18 11–28 0.4 0–5
Urbana 0
Tsumeb Rural 18 89 67–97 6 1–26 5 0.9–26
Urban 54 82 70–90 13 7–24 5 2–14
Usakos Rural 7 100 64–100 0 0–37 0 0–37
Urban 15 72 48–87 28 13–52 0 0–18
Walvis Bay Rurala 0
Urban 71 83 72–90 17 10–28 0 0–5
Windhoek
Central
Hospital
Rurala 0
Urban 31 84 68–93 16 7–32 0 0–11
CI, conﬁdence interval.
a Number too small to calculate meaningful estimates.
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This is the ﬁrst study of rubella antibody seroprevalence in
Namibia. The results are similar to those of previous studies in the
African region, which have reported rubella seropositive estimates
of 72–99% in women of reproductive age,7,16–24 and 53–95% in
pregnant women.18,25–41 These serosurvey results and evidence
from epidemiological investigations and CRS surveillance indicate
that rubella virus is circulating on the African continent, causing
rubella infections and CRS.8,42 For pregnant women, rubella
susceptibility is concerning because of the risk of CRS in the fetus.
These ﬁndings should be considered in light of limitations. First,
only pregnant women 15–44 years old were examined in this study,
and the ANC survey was not a random cross-section of the
population of pregnant women. Therefore, the results may not be
generalizable to all pregnant women in Namibia or to other age
groups and populations. When feasible, prospective, population-
based surveys could be considered to increase generalizability and
allow for the collection of information such as immunization status;
however, these studies are time- and resource-intensive, and
utilizing specimens already collected and stored might allow for
studies that would not otherwise be possible. Second, sample sizes
were small at the health district level, limiting conclusions regarding
geographic differences. Third, approximately one in four specimens
was not available for testing, which might have biased the results.
However, it is reassuring that the results from the multiple
imputation analysis were very similar to the reported ﬁndings.
Currently, inequity in access to rubella vaccine exists, and most
countries in Africa do not have RCV available in the public sector.
Because of this inequity, regions and countries not using rubella
vaccine in the EPI bear the greatest burden of rubella and CRS.43
Efforts should be made to ensure that resources are available for all
countries to introduce RCV into their EPI in accordance with WHO
recommendations, including an initial wide age-range nationwide
supplemental immunization activity (SIA) and periodic follow-up
SIAs to achieve and maintain population immunity to prevent and
eventually eliminate rubella and CRS.44
When considering the introduction of RCV into the national EPI,
a potential concern is a theoretical risk of increasing CRS incidence
through a phenomenon termed the ‘paradoxical effect’. This term
refers to a hypothetical situation in which persistently low
vaccination coverage over time might decrease rubella virus
circulation sufﬁciently, but not eliminate it entirely, shifting both
the average age of exposure to rubella virus and rubella
susceptibility from children to older age groups, including women
of childbearing age, and therefore increasing the incidence of CRS.
In such a scenario, however, it is unclear whether the absolute
number of CRS cases would actually increase over time compared
with the pre-vaccine era. A shift in susceptibility to older age
groups was previously documented in Greece and Costa Rica, but
these shifts reﬂected the implementation of suboptimal strategies.
In Greece, rubella vaccine was not introduced into the national EPI
and it was available only in the private sector, and an initial wide
age-range nationwide SIA was not implemented.45 In Costa Rica,
rubella vaccine introduction was initially limited to 1-year-old
children without an initial wide age-range nationwide SIA.46
Following the implementation of WHO-recommended strategies
for RCV introduction, including conducting an initial wide age-
range SIA,47 and as routine RCV vaccination coverage increases in
younger age groups, the percentage of rubella cases that occur
among older age groups might increase; however, the overall
rubella susceptibility in the population, the rubella absolute risk,
and the potential risk of CRS will decrease over time.
The disparity in rubella susceptibility among pregnant Namibian
women in rural settings compared with urban settings was not
unexpected. Consistent with these ﬁndings, rubella susceptibilityamong persons in rural settings was found to be higher than in
urban settings during the pre-vaccine era in countries throughout
Africa, Europe, the Americas, and Asia.7,48,49Moreover, the mean age
of infection of reported rubella cases in the pre-vaccine era in Africa
was previously found to be signiﬁcantly higher in rural settings
compared to urban settings.7 This was likely due to longer inter-
epidemic periods and the occurrence of rubella infection at older
ages in areas with lower population densities and contact rates.
When introducing RCV, it is critical to ensure high vaccination
coverage in both urban and rural areas to prevent outbreaks. Until all
countries have introduced RCV and rubella virus transmission is
interrupted, the threat of rubella virus importations, including from
bordering countries, will remain a concern, particularly in rural
settings.
The Global Measles and Rubella Strategic Plan for 2012–2020
recognizes the need to achieve and maintain high levels of
population immunity by providing high vaccination coverage with
two doses of measles- and rubella-containing vaccines.3 Cross-
sectional measles and rubella serosurveys provide important
evidence to identify immunity gaps in populations and guide
vaccination strategies to achieve elimination goals. Serological
survey results should be considered along with estimated
vaccination coverage and surveillance data to identify susceptible
age groups or areas that need to be covered by vaccination
activities, decide on vaccine introduction strategies, and determine
target age groups and geographic areas for SIAs. In Namibia, based
on the results from this study as well as other data sources
indicating low measles seropositivity among adults, the MoHSS is
considering implementing a nationwide SIA with measles–rubella
vaccine among persons aged 9 months to 39 years, a target
population of 1.8 million persons.50 These efforts will be a historic
ﬁrst step on the path to achieve measles and rubella elimination in
Namibia, if high coverage with measles–rubella vaccine can be
achieved and maintained.
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